RAI- REFRACTORY PAPILLARY THYROID CARCINOMA: ONE OF THE FIRST PATIENTS TO USE LENVATINIB IN THE COUNTRY, CASE REPORT (Atena Editora)

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributor.authorPASTORELLO, JULIA-
Autor(es): dc.contributor.authorLANDO, EMANUELA-
Autor(es): dc.contributor.authorBUENO, MARINA RACTZ-
Autor(es): dc.contributor.authorAMARAL, CAMILA DOS SANTOS DO-
Autor(es): dc.contributor.authorCECHETTI, CRISTIANE PAGNUSSAT-
Data de aceite: dc.date.accessioned2022-04-05T14:51:14Z-
Data de disponibilização: dc.date.available2022-04-05T14:51:14Z-
Data de envio: dc.date.issued2022-03-21-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/700980-
Resumo: dc.description.abstractINTRODUCTION: Thyroid cancer represents the most common tumor in women, approximately 10 to 20% of differentiated thyroid carcinomas (DTC) develop metastases, failure in treatment with iodine occurs in 50% of cases. The advent of Tyrosine Kinase Inhibitors (TKIs) has undergone a radical change in the pattern of treatment for DTC. OBJECTIVES: To report a case of Rai- refractory metastatic DTC, whose patient is one of the first to use lenvatinib in the country. CONCLUSIONS: With treatment, a patient under surveillance for metastatic diseases and multiple treatment line, exhibited response rates consistent with literary data, decreasing biochemical markers and manageable toxicity.pt_BR
Idioma: dc.language.isoenpt_BR
Palavras-chave: dc.subjectCARCINOMApt_BR
Título: dc.titleRAI- REFRACTORY PAPILLARY THYROID CARCINOMA: ONE OF THE FIRST PATIENTS TO USE LENVATINIB IN THE COUNTRY, CASE REPORT (Atena Editora)pt_BR
Tipo de arquivo: dc.typelivro digitalpt_BR
Aparece nas coleções:Livros digitais

Mostrar registro simples do item Visualizar estatísticas

Avaliação

1 2 3 4 5

Conteúdo acessível em Libras usando o VLibras Widget com opções dos Avatares Ícaro, Hosana ou Guga. Conteúdo acessível em Libras usando o VLibras Widget com opções dos Avatares Ícaro, Hosana ou Guga.